FDA con­verts Foghorn's par­tial hold on blood can­cer study to a full pause

Foghorn Ther­a­peu­tics’ flag­ship pro­gram has tak­en an­oth­er hit as the FDA has told the com­pa­ny to press hard­er on the brakes for a blood can­cer treat­ment.

The biotech an­nounced Tues­day that reg­u­la­tors have placed a full clin­i­cal hold on the Phase I dose es­ca­la­tion study of FHD-286. The can­di­date is meant to act as an in­hibitor of BRG1/BRM, in re­lapsed and/or acute myel­oge­nous leukemia (AML) and myelodys­plas­tic syn­drome (MDS).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER